FDA accepts Santhera, ReveraGen’s vamorolone NDA to treat DMD

[cafead]

via Santhera Pharmaceuticals and ReveraGen BioPharma have announced the acceptance of vamorolone’s new drug application (NDA) for filing by the US Food and Drug Administration (FDA) to treat Duchenne muscular dystrophy (DMD).

article source